Cargando…

Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors

Background: The timing of imaging for (68)gallium ((68)Ga)-PSMA and (68)Ga-DOTATOC are stated to be around 60 min post-injection (p.i.). In some lesions, late imaging (3–4 h p.i.) showed advantages. The aim of our evaluation was to demonstrate the relevance of an “early” late acquisition. Methods: W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Librizzi, Damiano, Eilsberger, Friederike, Ottenthaler, Stefan, Ebrahimifard, Ali, Luster, Markus, Yousefi, Behrooz H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136247/ https://www.ncbi.nlm.nih.gov/pubmed/37189670 http://dx.doi.org/10.3390/biomedicines11041052

Ejemplares similares

The utility of gallium-68 DOTATOC PET/CT in lymphangioleiomyomatosis
por: Gaffney, Brian, et al.
Publicado: (2021)

Splenosis Mimicking Relapse of a Neuroendocrine Tumor at Gallium-68-DOTATOC PET/CT
por: Treglia, Giorgio, et al.
Publicado: (2013)

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
por: Lenzo, Nat P., et al.
Publicado: (2018)

Pitfalls in Gallium-68 PSMA PET/CT Interpretation—A Pictorial Review
por: Shetty, Deepa, et al.
Publicado: (2018)

Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer
por: Kallur, Kumaraswamy G, et al.
Publicado: (2017)

Targeted Prostate Biopsy Using (68)Gallium PSMA-PET/CT for Image Guidance
por: Simopoulos, Demetrios N., et al.
Publicado: (2017)

Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT
por: Kaemmerer, Daniel, et al.
Publicado: (2011)

Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
por: Notni, Johannes, et al.
Publicado: (2012)

Incidental detection of a tumour on 68-Gallium DOTANOC PET/CT
por: Shah, Hina J., et al.
Publicado: (2014)

Diagnostic performance of (68)Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with (18)FEC PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2017)

The Impact of (68)Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours
por: Cuthbertson, Daniel J., et al.
Publicado: (2021)

Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by (18)fluorocholine PET/CT and its comparison with (68)gallium-DOTATOC PET/CT: Case report and review of the literature
por: Bongiovanni, Alberto, et al.
Publicado: (2017)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour
por: Rhee, Handoo, et al.
Publicado: (2016)

Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia: A Case Series
por: Rinzivillo, Maria, et al.
Publicado: (2022)

Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
por: Lawhn-Heath, Courtney, et al.
Publicado: (2020)

PET and PET/CT with (68)Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors
por: Sollini, Martina, et al.
Publicado: (2014)

SUN-314 Gallium-68 DOTATATE PET/CT for Preoperative Localization of Metastatic Insulinoma
por: Bratman, Russell, et al.
Publicado: (2019)

Optimization of Automated Radiosynthesis of Gallium-68-Labeled PSMA11 with Two [(68)Ge]Ge/[(68)Ga]Ga Generators: Fractional Elution or Prepurification?
por: Durieux, Flore, et al.
Publicado: (2023)

Gallium-68 labelled RGD PET/CT imaging of endothelial activation in COVID-19 patients
por: van Genugten, Evelien A. J., et al.
Publicado: (2023)

PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India
por: Sharma, Punit, et al.
Publicado: (2014)

[(68)Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning
por: Gehler, Barbara, et al.
Publicado: (2009)

Staging of neuroendocrine tumours: comparison of [(68)Ga]DOTATOC multiphase PET/CT and whole-body MRI
por: Schraml, C., et al.
Publicado: (2013)

The management impact of (68)gallium-tris(hydroxypyridinone) prostate-specific membrane antigen ((68)Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer
por: Kulkarni, Meghana, et al.
Publicado: (2019)

(68)Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy
por: Tan, Janice S.H., et al.
Publicado: (2019)

The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer
por: Hoffmann, Manuela A., et al.
Publicado: (2019)

A Generator-Produced Gallium-68 Radiopharmaceutical for PET Imaging of Myocardial Perfusion
por: Sharma, Vijay, et al.
Publicado: (2014)

Hydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68
por: Cusnir, Ruslan, et al.
Publicado: (2017)

Detection of Pulmonary Embolism with Gallium-68 Macroaggregated Albumin Perfusion PET/CT: An Experimental Study in Rabbits
por: Gültekin, Aziz, et al.
Publicado: (2020)

Standardisation of conventional and advanced iterative reconstruction methods for Gallium-68 multi-centre PET-CT trials
por: Krokos, Georgios, et al.
Publicado: (2021)

Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling
por: Tsionou, Maria Iris, et al.
Publicado: (2017)

Meningioma uptake of (68)Gallium-PSMA-11 as a pitfall on positron emission tomography/computer tomography
por: Courtney, Michael, et al.
Publicado: (2021)

Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE
por: Thisgaard, Helge, et al.
Publicado: (2021)

Role of (68)Ga-DOTATOC PET/CT in the Evaluation of Primary Pulmonary Carcinoids
por: Jindal, Tarun, et al.
Publicado: (2010)

Safety, tolerability and clinical implementation of ‘ready-to-use’ (68)gallium-DOTA0-Tyr3-octreotide ((68)Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
por: Manoharan, Prakash, et al.
Publicado: (2020)

Gallium-68 Ventilation/Perfusion PET-CT and CT Pulmonary Angiography for Pulmonary Embolism Diagnosis: An Interobserver Agreement Study
por: Le Pennec, Romain, et al.
Publicado: (2021)

In Vivo Trafficking of the Anticancer Drug Tris(8-Quinolinolato) Gallium (III) (KP46) by Gallium-68/67 PET/SPECT Imaging
por: Darwesh, Afnan M. F., et al.
Publicado: (2023)

Treatment of a mixed acinar-endocrine carcinoma with uptake on (68)Gallium-DOTATOC positron emission tomography-computed tomography: A case report
por: De Both, Anneleen, et al.
Publicado: (2017)

68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor
por: Shell, Jasmine, et al.
Publicado: (2018)

Usefulness of (68)Ga-DOTATOC PET/CT to localize the culprit tumor inducing osteomalacia
por: Lee, Dong Yun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_is4u9hn2h5nrq9li2dm7i8r71n